Document Detail


The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension.
MedLine Citation:
PMID:  22733464     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with resistant hypertension are at risk for poor outcomes. Medication adherence and intensification improve blood pressure (BP) control; however, little is known about these processes or their association with outcomes in resistant hypertension. This retrospective study included patients from 2002 to 2006 with incident hypertension from 2 health systems who developed resistant hypertension or uncontrolled BP despite adherence to ≥3 antihypertensive medications. Patterns of hypertension treatment, medication adherence (percentage of days covered), and treatment intensification (increase in medication class or dose) were described in the year after resistant hypertension identification. Then, the association between medication adherence and intensification with 1-year BP control was assessed controlling for patient characteristics. Of the 3550 patients with resistant hypertension, 49% were male, and mean age was 60 years. One year after resistance hypertension determination, fewer patients were taking diuretics (77.7% versus 92.2%; P<0.01), β-blockers (71.2% versus 79.4%; P<0.01), and angiotensinogen-converting enzyme inhibitor/angiotensin receptor blocker (64.8% versus 70.1%; P<0.01) compared with baseline. Rates of BP control improved over 1 year (22% versus 55%; P<0.01). During this year, adherence was not associated with 1-year BP control (adjusted odds ratio, 1.18 [95% CI: 0.94-1.47]). Treatment was intensified in 21.6% of visits with elevated BP. Increasing treatment intensity was associated with 1-year BP control (adjusted odds ratio, 1.64 [95% CI, 1.58-1.71]). In this cohort of patients with resistant hypertension, treatment intensification but not medication adherence was significantly associated with 1-year BP control. These findings highlight the need to investigate why patients with uncontrolled BP do not receive treatment intensification.
Authors:
Stacie L Daugherty; J David Powers; David J Magid; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Julie A Schmittdiel; P Michael Ho
Related Documents :
7249334 - Beneficial effects of adding propranolol to multidose potassium cardioplegia.
3184964 - Myocardial protection in cyanotic neonatal lambs.
9018524 - Sodium alterations in isolated rat heart during cardioplegic arrest.
22639014 - Is it possible to manage hypertension and evaluate therapy without ambulatory blood pre...
7197884 - Results of allergy treatment on the eustachian tube in chronic serous otitis media.
9836134 - Cholesterol concentrations and cardiovascular reactivity to stress in african american ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-06-25
Journal Detail:
Title:  Hypertension     Volume:  60     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-20     Completed Date:  2012-12-13     Revised Date:  2013-08-13    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  303-9     Citation Subset:  IM    
Affiliation:
Division of Cardiology, University of Colorado School of Medicine, 12605 E 16th Ave, Mail Stop B130, PO Box 6511, Aurora, CO 80045, USA. stacie.daugherty@ucdenver.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / pharmacology,  therapeutic use
Antihypertensive Agents / pharmacology*,  therapeutic use*
Blood Pressure / drug effects*,  physiology
Diuretics / pharmacology,  therapeutic use
Dose-Response Relationship, Drug
Drug Resistance* / physiology
Female
Humans
Hypertension / drug therapy*,  physiopathology
Longitudinal Studies
Male
Medication Adherence*
Middle Aged
Registries
Retrospective Studies
Risk Factors
Treatment Outcome
Grant Support
ID/Acronym/Agency:
K08 HL103776/HL/NHLBI NIH HHS; K08HL103776/HL/NHLBI NIH HHS; U19HL91179-01/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Diuretics
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients...
Next Document:  Prediction of Cardiovascular Events and All-Cause Mortality With Brachial-Ankle Elasticity Index: A ...